This is also in line with clinical observations in AML, where the presence of mutated NPM1 in the absence of a FLT3 mutation identifies a subset of AML with favorable prognosis, while the subsequent acquisition of a FLT3 mutation confers an intermediate risk20. Here, NPM1 is linked to acute myeloid leukemia.